Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

NCT ID: NCT00063141

Last Updated: 2010-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1302 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-04-30

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan compared with irinotecan alone as second-line therapy following treatment with a fluoropyrimidine and oxaliplatin based, non-irinotecan-containing regimen.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

Group Type EXPERIMENTAL

cetuximab

Intervention Type DRUG

Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision

Irinotecan

Intervention Type DRUG

Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision

Arm B

Group Type ACTIVE_COMPARATOR

Irinotecan

Intervention Type DRUG

Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cetuximab

Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision

Intervention Type DRUG

Irinotecan

Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision

Intervention Type DRUG

Irinotecan

Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Erbitux

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically documented colorectal cancer which is EGFR-positive by immunohistochemistry \[IHC\] (may be based on archival samples) and is metastatic.
* Prior oxaliplatin administered for the first-line treatment of metastatic colorectal cancer.
* Prior fluoropyrimidine-containing regimen (5-fluorouracil \[5-FU\], capecitabine, or uracil/tegafur \[UFT\]), for the first-line treatment of metastatic disease.

Exclusion Criteria

* A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy
* Unresolved diarrhea, bowel obstruction, or history of inflammatory bowel disease
* Known or documented brain metastases
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role collaborator

Eli Lilly and Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ImClone Systems

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

E-mail: ClinicalTrials@ ImClone.com

Role: STUDY_CHAIR

Eli Lilly and Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ImClone Investigational Site

Tucson, Arizona, United States

Site Status

ImClone Investigational Site

Pine Bluff, Arkansas, United States

Site Status

ImClone Investigational Site

Bakersfield, California, United States

Site Status

ImClone Investigational Site

Berkeley, California, United States

Site Status

ImClone Investigational Site

Beverly Hills, California, United States

Site Status

ImClone Investigational Site

Corona, California, United States

Site Status

ImClone Investigational Site

Gilroy, California, United States

Site Status

ImClone Investigational Site

Greenbrae, California, United States

Site Status

ImClone Investigational Site

Long Beach, California, United States

Site Status

ImClone Investigational Site

Los Angeles, California, United States

Site Status

ImClone Investigational Site

Los Angeles, California, United States

Site Status

ImClone Investigational Site

Montebello, California, United States

Site Status

ImClone Investigational Site

Orange, California, United States

Site Status

ImClone Investigational Site

Palm Springs, California, United States

Site Status

ImClone Investigational Site

Rancho Mirage, California, United States

Site Status

ImClone Investigational Site

San Diego, California, United States

Site Status

ImClone Investigational Site

Stockton, California, United States

Site Status

ImClone Investigational Site

Vallejo, California, United States

Site Status

ImClone Investigational Site

Aurora, Colorado, United States

Site Status

ImClone Investigational Site

Denver, Colorado, United States

Site Status

ImClone Investigational Site

New Haven, Connecticut, United States

Site Status

ImClone Investigational Site

New London, Connecticut, United States

Site Status

ImClone Investigational Site

Norwich, Connecticut, United States

Site Status

ImClone Investigational Site

Stamford, Connecticut, United States

Site Status

ImClone Investigational Site

Fort Myers, Florida, United States

Site Status

ImClone Investigational Site

Fort Myers, Florida, United States

Site Status

ImClone Investigational Site

Inverness, Florida, United States

Site Status

ImClone Investigational Site

Jacksonville, Florida, United States

Site Status

ImClone Investigational Site

Jacksonville, Florida, United States

Site Status

ImClone Investigational Site

Jacksonville, Florida, United States

Site Status

ImClone Investigational Site

Lakeland, Florida, United States

Site Status

ImClone Investigational Site

Miami, Florida, United States

Site Status

ImClone Investigational Site

New Port Richey, Florida, United States

Site Status

ImClone Investigational Site

Orlando, Florida, United States

Site Status

ImClone Investigational Site

Port Saint Lucie, Florida, United States

Site Status

ImClone Investigational Site

Atlanta, Georgia, United States

Site Status

ImClone Investigational Site

Atlanta, Georgia, United States

Site Status

ImClone Investigational Site

Columbus, Georgia, United States

Site Status

ImClone Investigational Site

Macon, Georgia, United States

Site Status

ImClone Investigational Site

Savannah, Georgia, United States

Site Status

ImClone Investigational Site

Tucker, Georgia, United States

Site Status

ImClone Investigational Site

Honolulu, Hawaii, United States

Site Status

ImClone Investigational Site

Naperville, Illinois, United States

Site Status

ImClone Investigational Site

South Bend, Indiana, United States

Site Status

ImClone Investigational Site

Kansas City, Kansas, United States

Site Status

ImClone Investigational Site

Overland Park, Kansas, United States

Site Status

ImClone Investigational Site

Lexington, Kentucky, United States

Site Status

ImClone Investigational Site

Louisville, Kentucky, United States

Site Status

ImClone Investigational Site

Richmond, Kentucky, United States

Site Status

ImClone Investigational Site

Baton Rouge, Louisiana, United States

Site Status

ImClone Investigational Site

Lafayette, Louisiana, United States

Site Status

ImClone Investigational Site

Metairie, Louisiana, United States

Site Status

ImClone Investigational Site

Shreveport, Louisiana, United States

Site Status

ImClone Investigational Site

Baltimore, Maryland, United States

Site Status

ImClone Investigational Site

Frederick, Maryland, United States

Site Status

ImClone Investigational Site

Boston, Massachusetts, United States

Site Status

ImClone Investigational Site

Ann Arbor, Michigan, United States

Site Status

ImClone Investigational Site

Detroit, Michigan, United States

Site Status

ImClone Investigational Site

Southfield, Michigan, United States

Site Status

ImClone Investigational Site

Minneapolis, Minnesota, United States

Site Status

ImClone Investigational Site

Robbinsdale, Minnesota, United States

Site Status

ImClone Investigational Site

Saint Louis Park, Minnesota, United States

Site Status

ImClone Investigational Site

Jackson, Mississippi, United States

Site Status

ImClone Investigational Site

Kansas City, Missouri, United States

Site Status

ImClone Investigational Site

Rolla, Missouri, United States

Site Status

ImClone Investigational Site

St Louis, Missouri, United States

Site Status

ImClone Investigational Site

Trenton, New Jersey, United States

Site Status

ImClone Investigational Site

Voorhees Township, New Jersey, United States

Site Status

ImClone Investigational Site

Albany, New York, United States

Site Status

ImClone Investigational Site

East Setauket, New York, United States

Site Status

ImClone Investigational Site

Latham, New York, United States

Site Status

ImClone Investigational Site

Mineola, New York, United States

Site Status

ImClone Investigational Site

New York, New York, United States

Site Status

ImClone Investigational Site

Rexford, New York, United States

Site Status

ImClone Investigational Site

Stony Brook, New York, United States

Site Status

ImClone Investigational Site

The Bronx, New York, United States

Site Status

ImClone Investigational Site

Valhalla, New York, United States

Site Status

ImClone Investigational Site

Durham, North Carolina, United States

Site Status

ImClone Investigational Site

Greenville, North Carolina, United States

Site Status

ImClone Investigational Site

High Point, North Carolina, United States

Site Status

ImClone Investigational Site

Raleigh, North Carolina, United States

Site Status

ImClone Investigational Site

Winston-Salem, North Carolina, United States

Site Status

ImClone Investigational Site

Winston-Salem, North Carolina, United States

Site Status

ImClone Investigational Site

Bismarck, North Dakota, United States

Site Status

ImClone Investigational Site

Cincinnati, Ohio, United States

Site Status

ImClone Investigational Site

Cleveland, Ohio, United States

Site Status

ImClone Investigational Site

Columbus, Ohio, United States

Site Status

ImClone Investigational Site

Dayton, Ohio, United States

Site Status

ImClone Investigational Site

Newark, Ohio, United States

Site Status

ImClone Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

ImClone Investigational Site

Hershey, Pennsylvania, United States

Site Status

ImClone Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

ImClone Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

ImClone Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

ImClone Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

ImClone Investigational Site

Greenville, South Carolina, United States

Site Status

ImClone Investigational Site

Knoxville, Tennessee, United States

Site Status

ImClone Investigational Site

Memphis, Tennessee, United States

Site Status

ImClone Investigational Site

Nashville, Tennessee, United States

Site Status

ImClone Investigational Site

Austin, Texas, United States

Site Status

ImClone Investigational Site

Dallas, Texas, United States

Site Status

ImClone Investigational Site

Houston, Texas, United States

Site Status

ImClone Investigational Site

Plano, Texas, United States

Site Status

ImClone Investigational Site

Temple, Texas, United States

Site Status

ImClone Investigational Site

Ogden, Utah, United States

Site Status

ImClone Investigational Site

Arlington, Virginia, United States

Site Status

ImClone Investigational Site

Danville, Virginia, United States

Site Status

ImClone Investigational Site

Newport News, Virginia, United States

Site Status

ImClone Investigational Site

Richmond, Virginia, United States

Site Status

ImClone Investigational Site

Seattle, Washington, United States

Site Status

ImClone Investigational Site

Spokane, Washington, United States

Site Status

ImClone Investigational Site

Spokane, Washington, United States

Site Status

ImClone Investigational Site

Walla Walla, Washington, United States

Site Status

ImClone Investigational Site

Green Bay, Wisconsin, United States

Site Status

ImClone Investigational Site

Madison, Wisconsin, United States

Site Status

ImClone Investigational Site

Milwaukee, Wisconsin, United States

Site Status

ImClone Investigational Site

Perth, Australian Capital Territory, Australia

Site Status

ImClone Investigational Site

Sydney, Australian Capital Territory, Australia

Site Status

ImClone Investigational Site

Sydney, New South Wales, Australia

Site Status

ImClone Investigational Site

Wollongong, New South Wales, Australia

Site Status

ImClone Investigational Site

South Brisbane, Queensland, Australia

Site Status

ImClone Investigational Site

Adelaide, South Australia, Australia

Site Status

ImClone Investigational Site

Wien, , Australia

Site Status

ImClone Investigational Site

Graz, , Austria

Site Status

ImClone Investigational Site

Salzburg, , Austria

Site Status

ImClone Investigational Site

Vienna, , Austria

Site Status

ImClone Investigational Site

Wein, , Austria

Site Status

ImClone Investigational Site

Charleroi, , Belgium

Site Status

ImClone Investigational Site

Brno, , Czechia

Site Status

ImClone Investigational Site

Olomouc, , Czechia

Site Status

ImClone Investigational Site

Prague, , Czechia

Site Status

ImClone Investigational Site

Helsinki, , Finland

Site Status

ImClone Investigational Site

Avignon, , France

Site Status

ImClone Investigational Site

Marseille, , France

Site Status

ImClone Investigational Site

Nice, , France

Site Status

ImClone Investigational Site

Saint-Herblain, , France

Site Status

ImClone Investigational Site

Aschaffenburg, , Germany

Site Status

ImClone Investigational Site

Augsburg, , Germany

Site Status

ImClone Investigational Site

Dessau, , Germany

Site Status

ImClone Investigational Site

Dortmund, , Germany

Site Status

ImClone Investigational Site

Essen, , Germany

Site Status

ImClone Investigational Site

Hamburg, , Germany

Site Status

ImClone Investigational Site

Hanburg, , Germany

Site Status

ImClone Investigational Site

Kaiserslautern, , Germany

Site Status

ImClone Investigational Site

Kassel, , Germany

Site Status

ImClone Investigational Site

Magdeburg, , Germany

Site Status

ImClone Investigational Site

Mainz, , Germany

Site Status

ImClone Investigational Site

Mannheim, , Germany

Site Status

ImClone Investigational Site

Muchnhen, , Germany

Site Status

ImClone Investigational Site

München, , Germany

Site Status

ImClone Investigational Site

Regensburg, , Germany

Site Status

ImClone Investigational Site

Saarbrücken, , Germany

Site Status

ImClone Investigational Site

Stralsund, , Germany

Site Status

ImClone Investigational Site

Stuttgart, , Germany

Site Status

ImClone Investigational Site

Hong Kong, , Hong Kong

Site Status

ImClone Investigational Site

Rozzano, Milano, Italy

Site Status

ImClone Investigational Site

Ancona, , Italy

Site Status

ImClone Investigational Site

Bergamo, , Italy

Site Status

ImClone Investigational Site

Candiolo, , Italy

Site Status

ImClone Investigational Site

Florence, , Italy

Site Status

ImClone Investigational Site

Genova, , Italy

Site Status

ImClone Investigational Site

Livomo, , Italy

Site Status

ImClone Investigational Site

Milan, , Italy

Site Status

ImClone Investigational Site

Modena, , Italy

Site Status

ImClone Investigational Site

Napoli, , Italy

Site Status

ImClone Investigational Site

Perugia, , Italy

Site Status

ImClone Investigational Site

Reggio Emilia, , Italy

Site Status

ImClone Investigational Site

Roma, , Italy

Site Status

ImClone Investigational Site

Rome, , Italy

Site Status

ImClone Investigational Site

Apeldoorn, , Netherlands

Site Status

ImClone Investigational Site

Dordrecht, , Netherlands

Site Status

ImClone Investigational Site

Montebello, Oslo County, Norway

Site Status

ImClone Investigational Site

Oslo, , Norway

Site Status

ImClone Investigational Site

Porto, , Portugal

Site Status

ImClone Investigational Site

Bratislava, , Slovakia

Site Status

ImClone Investigational Site

Lund, , Sweden

Site Status

ImClone Investigational Site

Stockholm, , Sweden

Site Status

ImClone Investigational Site

Bern, , Switzerland

Site Status

ImClone Investigational Site

Liestal, , Switzerland

Site Status

ImClone Investigational Site

Zurich, , Switzerland

Site Status

ImClone Investigational Site

Foresterhill, Aberdeenshire, United Kingdom

Site Status

ImClone Investigational Site

Hull, Avon, United Kingdom

Site Status

ImClone Investigational Site

Glasgow, Central, United Kingdom

Site Status

ImClone Investigational Site

Poole, Dorset, United Kingdom

Site Status

ImClone Investigational Site

London, Greater London, United Kingdom

Site Status

ImClone Investigational Site

Bournemouth, Hampshire, United Kingdom

Site Status

ImClone Investigational Site

Guildford, Surrey, United Kingdom

Site Status

ImClone Investigational Site

Sutton, Surrey, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Czechia Finland France Germany Hong Kong Italy Netherlands Norway Portugal Slovakia Sweden Switzerland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CA225-006

Identifier Type: -

Identifier Source: org_study_id

NCT00065598

Identifier Type: -

Identifier Source: nct_alias

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase I/II Combination With Irinotecan- Erbitux
NCT00594984 COMPLETED PHASE1/PHASE2
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
NCT03446157 ACTIVE_NOT_RECRUITING PHASE2